inclusion criteria: 1. signing and dating of the informed consent form of the patient information leaflet (pil) by patients. 2. men and women aged 18 to 80 years inclusive at the time of signing the informed consent form in pil. 3. no difficulty with oral medication (e.g. swallowing disorder). 4. patient diagnosed with "coronavirus infection caused by sars-cov-2 (confirmed)1, moderate severity form\*" established in accordance with the interim guidelines of the russian ministry of health for the prevention, diagnosis and treatment of a new coronavirus infection (covid-19), (revision 6 of 28.04.2020). \*moderate severity form: fever above 38 °c, br above 22/min, dyspnea during exercise, pneumonia (confirmed by lung ct), spo2 \< 95%, c reactive protein (crp) serum level above 10 mg/l. 5. patient should be hospitalized no more than 48 hours before the start of the study therapy. 6. positive pcr result for presence of sars-cov-2 rna at screening phase (results obtained within 7 days prior to screening are appropriate). 7. patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. persons eligible for participation in the study: - women who have a negative pregnancy test and use the following contraceptives: barrier method (condom or occlusive cap (diaphragm or cervical/vaulted cap)) or double barrier method of contraception (condom or occlusive cap (diaphragm or cervical/vaulted cap) plus spermicide (foam/gel/film/cream/suppository)). women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause more than 1 year) or men with preserved reproductive function who use barrier contraceptives, as well as men with infertility or vasectomy in the past medical history.

inclusion criteria: 1. signing and dating of the informed consent form of the patient information leaflet (pil) by patients. 2. men and women aged 18 to 80 years inclusive at the time of signing the informed consent form in pil. 3. no difficulty with oral medication (e.g. swallowing disorder). 4. patient diagnosed with "coronavirus infection caused by sars-cov-2 (confirmed)1, moderate severity form\*" established in accordance with the interim guidelines of the russian ministry of health for the prevention, diagnosis and treatment of a new coronavirus infection (covid-19), (revision 6 of 28.04.2020). \*moderate severity form: fever above 38 °c, br above 22/min, dyspnea during exercise, pneumonia (confirmed by lung ct), spo2 \< 95%, c reactive protein (crp) serum level above 10 mg/l. 5. patient should be hospitalized no more than 48 hours before the start of the study therapy. 6. positive pcr result for presence of sars-cov-2 rna at screening phase (results obtained within 7 days prior to screening are appropriate). 7. patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. persons eligible for participation in the study: - women who have a negative pregnancy test and use the following contraceptives: barrier method (condom or occlusive cap (diaphragm or cervical/vaulted cap)) or double barrier method of contraception (condom or occlusive cap (diaphragm or cervical/vaulted cap) plus spermicide (foam/gel/film/cream/suppository)). women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause more than 1 year) or men with preserved reproductive function who use barrier contraceptives, as well as men with infertility or vasectomy in the past medical history.

inclusion criteria: signing and dating of the informed consent form of the patient information leaflet (pil) by patients. men and women aged 18 to 80 years inclusive at the time of signing the informed consent form in pil. no difficulty with oral medication (e.g. swallowing disorder). patient diagnosed with "coronavirus infection caused by sars-cov-2 (confirmed)1, moderate severity form*" established in accordance with the interim guidelines of the russian ministry of health for the prevention, diagnosis and treatment of a new coronavirus infection (covid-19), (revision 6 of 28.04.2020). *moderate severity form: fever above 38 °c, br above 22/min, dyspnea during exercise, pneumonia (confirmed by lung ct), spo2 < 95%, c reactive protein (crp) serum level above 10 mg/l. patient should be hospitalized no more than 48 hours before the start of the study therapy. positive pcr result for presence of sars-cov-2 rna at screening phase (results obtained within 7 days prior to screening are appropriate). patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. persons eligible for participation in the study: - women who have a negative pregnancy test and use the following contraceptives: barrier method (condom or occlusive cap (diaphragm or cervical/vaulted cap)) or double barrier method of contraception (condom or occlusive cap (diaphragm or cervical/vaulted cap) plus spermicide (foam/gel/film/cream/suppository)). women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause more than 1 year) or men with preserved reproductive function who use barrier contraceptives, as well as men with infertility or vasectomy in the past medical history.

inclusion criteria: signing and dating of the informed consent form of the patient information leaflet (pil) by patients. men and women aged 18 to 80 years inclusive at the time of signing the informed consent form in pil. no difficulty with oral medication (e.g. swallowing disorder). patient diagnosed with "coronavirus infection caused by sars-cov-2 (confirmed)1, moderate severity form*" established in accordance with the interim guidelines of the russian ministry of health for the prevention, diagnosis and treatment of a new coronavirus infection (covid-19), (revision 6 of 28.04.2020). *moderate severity form: fever above 38 °c, br above 22/min, dyspnea during exercise, pneumonia (confirmed by lung ct), spo2 < 95%, c reactive protein (crp) serum level above 10 mg/l. patient should be hospitalized no more than 48 hours before the start of the study therapy. positive pcr result for presence of sars-cov-2 rna at screening phase (results obtained within 7 days prior to screening are appropriate). patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. persons eligible for participation in the study: - women who have a negative pregnancy test and use the following contraceptives: barrier method (condom or occlusive cap (diaphragm or cervical/vaulted cap)) or double barrier method of contraception (condom or occlusive cap (diaphragm or cervical/vaulted cap) plus spermicide (foam/gel/film/cream/suppository)). women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause more than 1 year) or men with preserved reproductive function who use barrier contraceptives, as well as men with infertility or vasectomy in the past medical history.

inclusion criteria: 1. signing and dating of the informed consent form of the patient information leaflet (pil) by patients. 2. men and women aged 18 to 80 years inclusive at the time of signing the informed consent form in pil. 3. no difficulty with oral medication (e.g. swallowing disorder). 4. patient diagnosed with "coronavirus infection caused by sars-cov-2 (confirmed)1, moderate severity form*" established in accordance with the interim guidelines of the russian ministry of health for the prevention, diagnosis and treatment of a new coronavirus infection (covid-19), (revision 6 of 28.04.2020). *moderate severity form: fever above 38 °c, br above 22/min, dyspnea during exercise, pneumonia (confirmed by lung ct), spo2 < 95%, c reactive protein (crp) serum level above 10 mg/l. 5. patient should be hospitalized no more than 48 hours before the start of the study therapy. 6. positive pcr result for presence of sars-cov-2 rna at screening phase (results obtained within 7 days prior to screening are appropriate). 7. patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. persons eligible for participation in the study: - women who have a negative pregnancy test and use the following contraceptives: barrier method (condom or occlusive cap (diaphragm or cervical/vaulted cap)) or double barrier method of contraception (condom or occlusive cap (diaphragm or cervical/vaulted cap) plus spermicide (foam/gel/film/cream/suppository)). women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause more than 1 year) or men with preserved reproductive function who use barrier contraceptives, as well as men with infertility or vasectomy in the past medical history.

inclusion criteria: 1. signing and dating of the informed consent form of the patient information leaflet (pil) by patients. 2. men and women aged 18 to 80 years inclusive at the time of signing the informed consent form in pil. 3. no difficulty with oral medication (e.g. swallowing disorder). 4. patient diagnosed with "coronavirus infection caused by sars-cov-2 (confirmed)1, moderate severity form*" established in accordance with the interim guidelines of the russian ministry of health for the prevention, diagnosis and treatment of a new coronavirus infection (covid-19), (revision 6 of 28.04.2020). *moderate severity form: fever above 38 °c, br above 22/min, dyspnea during exercise, pneumonia (confirmed by lung ct), spo2 < 95%, c reactive protein (crp) serum level above 10 mg/l. 5. patient should be hospitalized no more than 48 hours before the start of the study therapy. 6. positive pcr result for presence of sars-cov-2 rna at screening phase (results obtained within 7 days prior to screening are appropriate). 7. patient's consent to use reliable contraceptive methods throughout the study and within 1 month for women and 3 months for men after its completion. persons eligible for participation in the study: - women who have a negative pregnancy test and use the following contraceptives: barrier method (condom or occlusive cap (diaphragm or cervical/vaulted cap)) or double barrier method of contraception (condom or occlusive cap (diaphragm or cervical/vaulted cap) plus spermicide (foam/gel/film/cream/suppository)). women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause more than 1 year) or men with preserved reproductive function who use barrier contraceptives, as well as men with infertility or vasectomy in the past medical history.